Cochrane · systematic review · CD009130

Rituximab for relapsing‐remitting multiple sclerosis

He, D, Guo, R, Zhang, F, et al. · Cochrane Database of Systematic Reviews · 2013 · Cochrane Library

SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
5
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 2 · 28.6%Very low 0 · 0%Low 5 · 71.4%Moderate 0 · 0%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Rituximab for relapsing‐remitting multiple sclerosis

Population: patients with relapsing‐remitting multiple sclerosis
7 questions
OutcomeEffectEvidenceStatus / GRADE
The annualised rate of relapse Scale from: 0 to infinity.
no estimate extracted1 study · 104 participantsLow
Downgraded: risk of bias, imprecision
The sum of the number of gadolinium‐enhancing T1‐weighted lesions Scale from: 0 to infinity.
no estimate extracted1 study · 104 participantsLow
Downgraded: risk of bias, imprecision
The number of patients with adverse effects
RR 0.99 [0.94, 1.05]1 study · 104 participantsLow
Downgraded: risk of bias, imprecision
The number of patients with serious adverse events
RR 0.91 [0.33, 2.52]1 study · 104 participantsLow
Downgraded: risk of bias, imprecision
The number of patients who withdrew or dropped out from the study because of AEs
RR 0.76 [0.13, 4.35]1 study · 104 participantsLow
Downgraded: risk of bias, imprecision
The number of patients with disability progression
no estimate extracted0 studies · 0 participantsUngraded
The time to confirmed disease progression
no estimate extracted0 studies · 0 participantsUngraded